Results 1 to 10 of about 100,759 (296)
Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols [PDF]
Pharmaceutics, 2022 Central nervous system (CNS) disorders, such as psychiatric disorders, neurodegeneration, chronic pain, stroke, brain tumor, spinal cord injury, and many other CNS diseases, would hugely benefit from specific and potent peptide pharmaceuticals and their ...
Wafaa Alabsi +4 more
doaj +4 more sources
Pharmaceutics, 2020 Nose-to-brain delivery represents a big challenge. In fact there is a large number of neurological diseases that require therapies in which the drug must reach the brain, avoiding the difficulties due to the blood−brain barrier (BBB) and the ...
Paolo Giunchedi +2 more
doaj +4 more sources
Nose-to-brain delivery of self-assembled curcumin-lactoferrin nanoparticles: Characterization, neuroprotective effect and in vivo pharmacokinetic study [PDF]
Frontiers in Bioengineering and Biotechnology, 2023 Curcumin (CUR) is a natural polyphenol extract with significant antioxidant and anti-inflammatory effects, which indicates its great potential for neuroprotection. Lactoferrin (LF), a commonly used oral carrier and targeting ligand, has not been reported
Linghui Li +6 more
doaj +2 more sources
Nasal Drug Delivery and Nose-to-Brain Delivery Technology Development Status and Trend Analysis: Based on Questionnaire Survey and Patent Analysis [PDF]
PharmaceuticsNasal administration is a non-invasive method of drug delivery that offers several advantages, including rapid onset of action, ease of use, no first-pass effect, and fewer side effects.
Yuanyuan Ge +9 more
doaj +2 more sources
Transnasal-brain delivery of nanomedicines for neurodegenerative diseases
Frontiers in Drug Delivery, 2023 Neurodegenerative diseases (NDs) have become a serious global health problem as the population ages. Traditionally, treatment strategies for NDs have included oral and intravenous administration; however, the blood–brain barrier (BBB) can prevent drugs ...
Xu Zhang +11 more
doaj +1 more source
Pharmaceutics, 2023 Rasagiline mesylate (RSM) is a hydrophilic drug with poor oral bioavailability (36%) because of hepatic first-pass metabolism. The present study focuses on delivering RSM directly to the brain through its inclusion within transferosomal in situ gel ...
Hala N. ElShagea +4 more
doaj +1 more source
Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease
Health Sciences Review, 2023 Alzheimer's disease (AD) is a neurodegenerative brain disorder that affects memory, thinking, concentration, and judgment, ultimately hindering a person's ability to perform routine daily activities.
Manisha Vohra +3 more
doaj +1 more source
Health Sciences Review, 2022 Central nervous system-related disorders are very difficult to manage with conventional therapeutics because of the selective and herculean nature of the blood-brain barrier which does not allow easy penetration of drug molecules into the brain.
Mayank Handa +4 more
doaj +1 more source
Intranasal Administration as a Route to Deliver Drugs to the Brain (Review)
Разработка и регистрация лекарственных средств, 2021 Introduction. Intranasal drug delivery from nose-to-brain is one of the promising approaches for the treatment of brain diseases including neurodegenerative diseases, stroke, brain tumors, etc.Text.
N. N. Porfiryeva +3 more
doaj +1 more source
Pharmaceutics, 2022 Intranasal administration is a promising route for brain drug delivery. However, it can be difficult to formulate drugs that have low water solubility into high strength intranasal solutions.
Patrícia C. Pires +3 more
doaj +1 more source